Tags

Type your tag names separated by a space and hit enter

Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study.
Aliment Pharmacol Ther 2006; 23(8):1235-40AP

Abstract

BACKGROUND

Cure rates for eradication of Helicobacter pylori appear to be decreasing, thus more effective therapies must be identified.

AIM

To evaluate the efficacy of bovine lactoferrin in the treatment of H. pylori infection.

METHODS

In a multicentered prospective study, 402 (mean age 52.4, range 19-84 years) H. pylori-positive patients were assigned to one of three regimens: group A - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days; group B - lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A; group C - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days.

RESULTS

Of the 402 patients, 389 completed the study. Six patients were discontinued due to side effects, one patient in group B died and six patients were lost to follow up. The eradication rate (intention-to-treat analysis) was 77% in group A (105/136), 73% in group B (97/132) and 90% in group C (120/134) (chi(2)-test P < 0.01). The incidence of side effects was 9.5% in group A, 9% in group B and 8.2% in group C (chi(2)-test P = 0.1).

CONCLUSION

This study demonstrates that bovine lactoferrin is an effective adjuvant to 7-day triple therapy for eradication of H. pylori infection.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

16611285

Citation

Di Mario, F, et al. "Bovine Lactoferrin for Helicobacter Pylori Eradication: an Open, Randomized, Multicentre Study." Alimentary Pharmacology & Therapeutics, vol. 23, no. 8, 2006, pp. 1235-40.
Di Mario F, Aragona G, Dal Bó N, et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther. 2006;23(8):1235-40.
Di Mario, F., Aragona, G., Dal Bó, N., Cavallaro, L., Marcon, V., Olivieri, P., ... Franzè, A. (2006). Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Alimentary Pharmacology & Therapeutics, 23(8), pp. 1235-40.
Di Mario F, et al. Bovine Lactoferrin for Helicobacter Pylori Eradication: an Open, Randomized, Multicentre Study. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1235-40. PubMed PMID: 16611285.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. AU - Di Mario,F, AU - Aragona,G, AU - Dal Bó,N, AU - Cavallaro,L, AU - Marcon,V, AU - Olivieri,P, AU - Benedetti,E, AU - Orzès,N, AU - Marin,R, AU - Tafner,G, AU - Chilovi,F, AU - De Bastiani,R, AU - Fedrizzi,F, AU - Franceschi,M, AU - Salvat,M H, AU - Monica,F, AU - Piazzi,L, AU - Valiante,F, AU - Vecchiati,U, AU - Cavestro,G M, AU - Comparato,G, AU - Iori,V, AU - Maino,M, AU - Leandro,G, AU - Pilotto,A, AU - Rugge,M, AU - Franzè,A, AU - ,, PY - 2006/4/14/pubmed PY - 2006/6/30/medline PY - 2006/4/14/entrez SP - 1235 EP - 40 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 23 IS - 8 N2 - BACKGROUND: Cure rates for eradication of Helicobacter pylori appear to be decreasing, thus more effective therapies must be identified. AIM: To evaluate the efficacy of bovine lactoferrin in the treatment of H. pylori infection. METHODS: In a multicentered prospective study, 402 (mean age 52.4, range 19-84 years) H. pylori-positive patients were assigned to one of three regimens: group A - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days; group B - lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A; group C - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days. RESULTS: Of the 402 patients, 389 completed the study. Six patients were discontinued due to side effects, one patient in group B died and six patients were lost to follow up. The eradication rate (intention-to-treat analysis) was 77% in group A (105/136), 73% in group B (97/132) and 90% in group C (120/134) (chi(2)-test P < 0.01). The incidence of side effects was 9.5% in group A, 9% in group B and 8.2% in group C (chi(2)-test P = 0.1). CONCLUSION: This study demonstrates that bovine lactoferrin is an effective adjuvant to 7-day triple therapy for eradication of H. pylori infection. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16611285/Bovine_lactoferrin_for_Helicobacter_pylori_eradication:_an_open_randomized_multicentre_study_ L2 - https://doi.org/10.1111/j.1365-2036.2006.02851.x DB - PRIME DP - Unbound Medicine ER -